Evidence map›Paper›PMID 42088894›Full record

ArticleFrontiers in oral health2026

Immunomodulatory mediators IL-33, soluble ST2, IL-10, IFN-

Swetha Acharya, Usha Hegde, Subba Rao Venkata Madhunapantula, Medha Karnik, Anirudh Balakrishna Acharya, Pushparaja Shetty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Swetha AcharyaDepartment of Oral Pathology and Microbiology, JSS Dental College and Hospital, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, India.
Usha HegdeDepartment of Oral Pathology and Microbiology, JSS Dental College and Hospital, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, India.
Subba Rao Venkata MadhunapantulaCenter of Excellence in Molecular Biology and Regenerative Medicine (CEMR) Laboratory (DST-FIST supported center and ICMR Collaborating Center of Excellence- ICMR-CCoE), Department of Biochemistry (DST-FIST supported department), JSS Medical College & Hospital, JSSAHER, Mysuru, India.
Medha KarnikCenter of Excellence in Molecular Biology and Regenerative Medicine (CEMR) Laboratory (DST-FIST supported center and ICMR Collaborating Center of Excellence- ICMR-CCoE), Department of Biochemistry (DST-FIST supported department), JSS Medical College & Hospital, JSSAHER, Mysuru, India.
Anirudh Balakrishna AcharyaDepartment of Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Pushparaja ShettyDepartment of Oral & Maxillofacial Pathology & Oral Microbiology, A.B. Shetty Memorial Institute of Dental Sciences, NITTE (Deemed to be University), Mangaluru, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin-33 (IL-33) and its receptor Suppression of tumorigenicity 2 (ST2), along with IL-10 and IFN- Aims: To evaluate whether IL-33 and ST2, in conjunction with their interactions with IL-10 and IFN- Materials and methods: Ninety participants were enrolled in this cross-sectional observational study and divided into three groups: Healthy controls (HC) ( Results: The analysis demonstrated a progressive and significant increase in IL-33, ST2, and IL-10 levels from HC to OPMDs to OSCC ( Conclusion: The panel of immunomodulatory mediators analysed here reflects a biologically relevant shift toward pro-tumorigenic inflammation and immune evasion, underscoring their role as biomarkers of malignant progression. Collectively, these immunomodulatory mediators demonstrated strong diagnostic accuracy in differentiating OSCC from OPMDs and showed potential for risk stratification.

Indexed as

interferon gamma (IFN-γ)interleukin-10 (IL-10)interleukin-33 (IL-33)interleukin-33 receptor (IL-33R)oral squamous cell carcinoma (OSCC)soluble suppression of tumorigenicity 2 (sST2)suppression of tumorigenicity 2 (ST2)

Identifiers

PMID42088894
PMCPMC13136695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.